Dermatology and Therapy最新文献

{"title":"Quantitative Evaluation of Nemolizumab Pharmacokinetics and Efficacy in Prurigo Nodularis: A Population Pharmacokinetics and Model-Based Meta-analysis Approach.","authors":"Tomoki Takechi, Junya Shimizu, Kenji Kabashima, Ichiro Ieiri","doi":"10.1007/s13555-025-01554-4","DOIUrl":"https://doi.org/10.1007/s13555-025-01554-4","url":null,"abstract":"<p><strong>Introduction: </strong>Nemolizumab is a humanized monoclonal antibody targeting interleukin-31 receptor A. It has shown efficacy in treating patients with prurigo nodularis (PN). In this study, we characterized the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of nemolizumab in patients with PN and compared its efficacy with that of another approved treatment, dupilumab, using a model-based meta-analysis (MBMA).</p><p><strong>Methods: </strong>We updated an existing population PK (PopPK) model developed for patients with atopic dermatitis (AD) by incorporating data from four clinical studies. The updated model validated the PK of nemolizumab in patients with PN, confirming its relevance and precision. Furthermore, we developed a population PD (PopPD) model to characterize treatment response and assessed changes in the weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) over time. To conduct an MBMA, we performed a systematic literature search of public databases to identify studies for modeling the success rate of achieving a ≥ 4-point improvement in the PP-NRS and a ≥ 2-point decrease in the Investigator's Global Assessment (IGA).</p><p><strong>Results: </strong>The updated PopPK model adequately described the serum concentration profile of nemolizumab in patients with PN, suggesting a similarity in the PK characteristics between AD and PN. The PopPD model successfully described the effects of the placebo and nemolizumab on PP-NRS. Six individual randomized controlled trials were eligible for the MBMA. Model simulations indicated that the success rates for PP-NRS and IGA were consistently higher for nemolizumab compared with dupilumab, up to 24 weeks.</p><p><strong>Conclusion: </strong>The PopPK and PopPD models well described the PK and PD profiles of nemolizumab in patients with PN. MBMA demonstrated that nemolizumab was superior to dupilumab in improving response rates in patients with PN. These findings, derived from pharmacometrics modeling and indirect comparison, may help inform future clinical studies and support the ongoing evaluation of nemolizumab in PN.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review.","authors":"Hussein Abdel Dayem, Anwar Al Hammadi, Ashraf Reda, Fatima Albreiki, Ayman Al Naeem, Ahmed Ameen, Mohamed Ahmed, Huda Rajab Ali, Mohamed Elrayes, Gozde Senay, Muna Al Murrawi","doi":"10.1007/s13555-025-01546-4","DOIUrl":"https://doi.org/10.1007/s13555-025-01546-4","url":null,"abstract":"<p><p>Alopecia areata is an inflammatory autoimmune disease that presents as non-scarring hair loss in adults and children and causes substantial psychological distress, economic burden, and reduced quality of life for those affected. Although steroids and immunosuppressants are common treatments for alopecia areata, results from studies of Janus kinase inhibitors in the systemic management of alopecia areata, including those from long-term efficacy and safety studies on the Janus kinase 1/2 inhibitor baricitinib, show promising results. Despite alopecia areata placing a burden on healthcare systems in the Middle East, published data on the overall prevalence, patient characteristics, and treatment landscape for alopecia areata across the region are sparse, and a lack of approved therapies and insufficient access to treatment are treatment obstacles. Herein, we describe the burden of alopecia areata on patients and healthcare systems, review publications from the United Arab Emirates (UAE) on alopecia areata, highlight gaps in the data, and review clinical trial publications on the management of alopecia areata with baricitinib, the first Janus kinase inhibitor approved for the treatment of alopecia areata in the UAE. A regional expert assessment of the burden of alopecia areata and unmet medical needs in the UAE is provided, along with an expert opinion on treating patients with severe alopecia areata.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clascoterone Stability When Combined with Topical Acne Medications In Vitro.","authors":"Zoe D Draelos, Matthew M Draelos, Kizito Kyeremateng, Nicholas Squittieri","doi":"10.1007/s13555-025-01553-5","DOIUrl":"https://doi.org/10.1007/s13555-025-01553-5","url":null,"abstract":"<p><strong>Introduction: </strong>Multimodal topical therapy is recommended by the American Academy of Dermatology for the treatment of acne vulgaris. However, no data are available regarding stability of clascoterone cream 1% when combined with other topical acne medications. The purpose of this study was to evaluate the stability of clascoterone in the presence of tretinoin, adapalene, dapsone, azelaic acid, benzoyl peroxide (BP)/clindamycin, BP/adapalene, and encapsulated BP.</p><p><strong>Methods: </strong>Clascoterone cream (0.5 mL) was layered over 0.5 mL of each of the other products on an individual microscope slide and incubated for 8 h at 37 °C. Material from the slides was extracted in methanol and tetrahydrofuran for high-pressure liquid chromatography mass spectrometry (1 mL/min flow rate; 30 °C). Combinations of clascoterone with tretinoin and adapalene were reinjected 12 h after the initial injections to confirm consistent clascoterone detection. Percent recovery of clascoterone for each combination was calculated from a standard curve serially diluted in methanol.</p><p><strong>Results: </strong>The mean percentage of clascoterone recovered after incubation with other drugs ranged from 98% to 119%, with 86% recovered following injection of clascoterone alone. Reinjected clascoterone-tretinoin and clascoterone-adapalene samples yielded clascoterone recovery percentages of 97% and 93%, respectively, both within 8% of those recovered from the initial injections.</p><p><strong>Conclusions: </strong>Clascoterone demonstrated consistent and reproducible stability in the presence of other topical acne medications.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145174118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcomes of Topical 5% Imiquimod Treatment for Lentigo Maligna: A Systematic Review.","authors":"Pablo Balado-Simó, Marc Hernández-Santacana, Daniel Morgado-Carrasco","doi":"10.1007/s13555-025-01552-6","DOIUrl":"https://doi.org/10.1007/s13555-025-01552-6","url":null,"abstract":"<p><strong>Introduction: </strong>Lentigo maligna (LM) is a melanoma in situ frequently located on sun-exposed areas. While surgery is the standard of care, topical 5% imiquimod has emerged as a non-invasive alternative for patients unsuitable for surgery. However, existing literature often lacks long-term follow-up. This systematic review aims to assess the long-term effectiveness and safety of imiquimod in LM, focusing on studies with ≥ 48 months of follow-up.</p><p><strong>Methods: </strong>A comprehensive search was conducted in MEDLINE (PubMed) and the Cochrane Library up to July 2025. Inclusion criteria comprised original studies reporting on LM treated with 5% imiquimod with ≥ 48 months of follow-up.</p><p><strong>Results: </strong>Six studies (422 patients) met the inclusion criteria: one prospective and five retrospective studies. Median follow-up ranged from 49 to 205 months. Clinical clearance rates varied between 63.6% and 97.1%, with recurrence rates ranging from 0% to 20.7%. Histological clearance was inconsistently confirmed. Progression to lentigo maligna melanoma (LMM) was infrequent (9/422). One retrospective study (n = 111) reported melanoma-specific survival at 10 years as 100% (95% CI 90.5-100%). The presence of a robust local inflammatory response was consistently associated with improved outcomes. Adverse effects were mostly mild and self-limiting. Overall evidence certainty was moderate to low.</p><p><strong>Discussion: </strong>This review provides evidence that 5% imiquimod may offer durable responses for LM, particularly in patients who develop a marked inflammatory reaction. Nevertheless, recurrence and occasional progression to LMM underscore the need for long-term monitoring, ideally combining clinical, dermoscopic and histological assessment. Lack of standardized treatment protocols and heterogeneous definitions of response limit comparability between studies.</p><p><strong>Conclusion: </strong>Topical 5% imiquimod may be a viable long-term treatment option for selected patients with LM, although the evidence is scarce and mostly of low quality. A strong local inflammatory response appears predictive of clinical success. Given the potential for late recurrence and risk of progression to LMM, long-term structured follow-up is essential. Future prospective studies with uniform protocols are warranted.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physician-Reported Treatment Patterns in Moderate to Severe Chronic Hand Eczema: the RWEAL Multinational Medical Chart Review.","authors":"Ana Giménez-Arnau, Anthony Bewley, Christian Apfelbacher, Maria Concetta Fargnoli, Bleuenn Rault, Alexanne Morillo, Douglas Maslin, Jenny M Norlin, Marie-Noëlle Crépy, Sonja Molin","doi":"10.1007/s13555-025-01534-8","DOIUrl":"https://doi.org/10.1007/s13555-025-01534-8","url":null,"abstract":"<p><strong>Introduction: </strong>Evidence for moderate to severe chronic hand eczema (CHE) treatments in clinical practice is limited. The objective was to investigate treatment patterns in patients with moderate to severe CHE, and in those with an inadequate response to topical corticosteroids (TCS) or in whom TCS were contraindicated.</p><p><strong>Methods: </strong>This was a multinational retrospective physician chart review. Physicians who routinely diagnosed and treated CHE were recruited in Canada, France, Germany, Italy, Spain, and the UK and provided data on adult patients with moderate to severe CHE treated with TCS over the past 12 months or for whom TCS were contraindicated.</p><p><strong>Results: </strong>A total of 292 physicians provided data on 1939 patients. Worst severity of CHE in the 12-month study period was judged by the physician to be moderate in 56.8% and severe in 43.2% of patients. Overall, 6.7% of patients received topical calcineurin inhibitors, 3.9% phototherapy, 6.8% alitretinoin, 11.1% traditional orals (acitretin, azathioprine, oral corticosteroids, cyclosporine, methotrexate), 8.0% biologics, and 1.7% oral Janus kinase (JAK) inhibitors. An inadequate response or contraindication to TCS was reported in 39.9% of patients (27.4% progressed to phototherapy/systemics; 12.1% with adverse events or an inadequate response to high/ultra-high potency TCS, and 0.4% contraindicated). Among these patients, the highest line of treatment during the 12-month period was biologics in 29.2%, alitretinoin in 22.3%, oral JAK inhibitors in 5.1%, traditional orals in 33.3%, and phototherapy in 9.6% of patients. There were no significant differences in phototherapy/systemic treatments between patients with moderate and severe disease in this subgroup.</p><p><strong>Conclusions: </strong>Despite being a first-line treatment, 40% of patients with CHE were inadequately treated with or contraindicated to TCS. Over one-quarter of patients progressed to phototherapy or systemic therapy. These results suggest a lack of effective and well-tolerated topical treatment options in CHE. Graphical Abstract available for this article.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aquagenic Pruritus Questionnaire: Predicting Myeloproliferative Neoplasms in Patients with Aquagenic Pruritus.","authors":"Felix Witte, Elke Weisshaar, Martin Metz, Steffen Koschmieder, Susanne Isfort, Andreas E Kremer, Martin Griesshammer, Svenja Royeck, Sonja Ständer, Claudia Zeidler","doi":"10.1007/s13555-025-01548-2","DOIUrl":"https://doi.org/10.1007/s13555-025-01548-2","url":null,"abstract":"<p><strong>Introduction: </strong>Aquagenic pruritus (AP) is an underrecognized condition in which patients perceive itch following contact with water on clinically non-lesional skin. AP is frequent in patients suffering from myeloproliferative neoplasms (MPN) such as polycythemia vera and may manifest several years prior to MPN diagnosis. To date, there is no validated patient-reported outcome measure (PROM) assessing AP and its association with MPN.</p><p><strong>Methods: </strong>In this multiphase study, eight questions relevant to AP were developed and validated in 77 patients with AP and 50 patients with chronic non-aquagenic pruritus (CP). After reduction to those questions relevant for distinguishing between AP with and without MPN, the resulting questionnaire was validated in 76 patients with AP (37 with MPN) and 76 with CP. The predictive power of the questionnaire's score was retrospectively tested in the first cohort.</p><p><strong>Results: </strong>Four key questions were identified as central to differentiating MPN in AP, forming the basis of the AP questionnaire (APQ). Sensitivity and specificity of the score reached 97.3% and 79.5%, respectively. The APQ classified five patients with AP with MPN who were diagnosed with MPN at a later stage.</p><p><strong>Conclusion: </strong>APQ is the first validated PROM for patients with AP, detecting a potential relationship to MPN with high sensitivity. APQ is a useful addition to standard of care in patients suffering from AP, potentially shortening the delay of MPN diagnosis.</p><p><strong>Trial registration: </strong>German Clinical Trials Registry, DRKS 00006075.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145174146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Tolerability of a Facial Serum Before and After Ablative Fractional Carbon Dioxide Laser: A Randomized Controlled Trial on Chinese Women.","authors":"Jing Li, Xingzuo Liu, Zhiming Zhang, Hequn Wang, Jingbo Ma, Yanwen Jiang, Le Sheng, Shumei Li, Ji Zhang, Xinrong Lin, Kungchi Hsu, Yidong Tu, Andrew Steel, Yan Wu, Frederic Flament","doi":"10.1007/s13555-025-01531-x","DOIUrl":"https://doi.org/10.1007/s13555-025-01531-x","url":null,"abstract":"<p><strong>Introduction: </strong>Ablative fractional CO₂ laser treatment (AFCO₂) can cause immediate erythema, pain, and complications such as prolonged erythema and post-inflammatory hyperpigmentation. This study investigated whether the use of a serum before and after AFCO₂ could accelerate skin recovery and relieve complications.</p><p><strong>Methods: </strong>This randomized controlled trial included 72 healthy Chinese women with acne scars who intended to undergo AFCO₂; 64 (32 in each group) completed the study and were included in the analysis. The participants in the serum group applied the study serum for 2 weeks in the preoperative (D0 and D14) and post-treatment stages (D32 and D39), with additional product usage of standard products, including standard cleanser, moisturizer, and sunscreen, for all participants (both groups). Transepidermal water loss (TEWL), skin hydration, and skin qualities were evaluated throughout the entire study. Clinical assessment was conducted at D0 (baseline and time immediately after product application); D14; D15 (directly after procedure treatment); D16, D18, D22, and D25 (1 day, 3 days, 7 and 10 days after CO₂ laser treatment); and during the post-treatment period at D32 and D39 (1 and 2 weeks after self-recovery).</p><p><strong>Results: </strong>TEWL improvement was significantly better in the serum group than in the control group throughout the study (p < 0.001), including pre-treatment (p = 0.043), self-recovery (D15-D31) (p < 0.001), and post-treatment (p = 0.027) stages. In the post-treatment stage, the improvement in skin hydration with the serum was significantly better than in the control group (p < 0.001). The serum group showed significantly better improvements in smoothness (p = 0.001), brightness (p = 0.016), and overall healthy appearance (p = 0.001) compared with controls.</p><p><strong>Conclusion: </strong>Peri-AFCO₂ application of the serum can facilitate faster postoperative recovery and can help reduce postoperative erythema and discomfort with satisfying tolerance. The use of the serum can enhance effectiveness and satisfaction with AFCO₂ treatment.</p><p><strong>Trial registration: </strong>This trial was retrospectively registered on 30 June 2025: ISRCTN identifier ISRCTN60519611.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Trends in Systemic Treatment for Pediatric Psoriasis in the USA between 2015 and 2021.","authors":"Anna Ramond, Theresa Rosario-Jansen, Xinyu Yang, Amy S Paller","doi":"10.1007/s13555-025-01545-5","DOIUrl":"https://doi.org/10.1007/s13555-025-01545-5","url":null,"abstract":"<p><strong>Introduction: </strong>Biologics may have altered the standard of care for pediatric psoriasis, the prevalence of which has not been studied since 2015. The objective of this study was to provide an update of the prevalence of and treatment landscape for pediatric psoriasis in the USA, highlighting the current burden of the condition and the need for improved disease awareness.</p><p><strong>Methods: </strong>In this retrospective cohort study, US claims data (July 2015 to October 2021) from the MarketScan^® database were used to estimate the prevalence of overall plaque psoriasis and moderate to severe plaque psoriasis in pediatric patients (aged 6-17 years) from 2016 to 2020. Systemic/phototherapy treatment use (per 100 patient-years [PY]) in moderate to severe pediatric patients was reported from 2017 to 2021.</p><p><strong>Results: </strong>A total of 8935 pediatric patients with psoriasis were included, of whom 1448 had moderate to severe psoriasis. In 2020, the estimated overall pediatric psoriasis prevalence based on coding was 117.4/100,000, and it was 18.4/100,000 for moderate to severe psoriasis. Between 2017 and 2021, the use of non-biologic systemic treatments (2017: 36.3/100 PY; 2021: 14.1/100 PY) and phototherapy treatments (2017: 41.3/100 PY; 2021: 4.3/100 PY) decreased, while the use of biologics increased (2017: 41.5/100 PY; 2021: 56.4/100 PY). Interleukin inhibitor use increased (2017: 5.0/100 PY; 2021: 37.6/100 PY), while tumor necrosis factor (TNF) inhibitor use decreased (2017: 37.5/100 PY; 2021: 20.2/100 PY). Ustekinumab use increased the most (2017: 4.8/100 PY; 2021: 30.4/100 PY), followed by ixekizumab (2017: 0.2/100 PY; 2021: 7.2/100 PY).</p><p><strong>Conclusions: </strong>In 2020, psoriasis remained relatively uncommon among US children and adolescents, with 15.9% having moderate to severe psoriasis. Meanwhile, treatment for moderate to severe psoriasis shifted from older treatments, particularly non-biologic systemics and TNF inhibitors, toward newer, more efficacious interleukin inhibitors.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort.","authors":"Pilar Villodre Lozano, Tania Díaz Corpas, Altea Esteve Martínez, Fernando Millán Parrilla, Montserrat Évole Buselli, Jose María Martín Hernández, Laura Berbegal de Gracia, Francisco Javier Melgosa Ramos, Javier Auban Pariente, Javier Sánchez Arraez","doi":"10.1007/s13555-025-01547-3","DOIUrl":"https://doi.org/10.1007/s13555-025-01547-3","url":null,"abstract":"<p><strong>Introduction: </strong>Atopic dermatitis (AD) is a common chronic inflammatory disease during adolescence, with severe forms having a particularly high impact on patients' quality of life. Several therapeutic options are currently approved for the treatment of AD in individuals over 12 years of age. This study evaluated the efficacy and safety of tralokinumab in adolescent patients, with a particular focus on identifying which patient profiles may derive the greatest benefit from this therapy.</p><p><strong>Methods: </strong>A retrospective multicenter study was conducted across nine Spanish hospitals, including patients from 12 to 17 years old with moderate-to-severe AD treated with tralokinumab.</p><p><strong>Results: </strong>A total of 27 patients were included, with a mean age of 14.8 years. Nine had previously received treatment with dupilumab, five due to primary or secondary failure, and four due to adverse events. One patient had been treated with upadacitinib, which was discontinued because of primary failure and acne. A statistically significant reduction was achieved in Eczema Area and Severity Index (EASI), pruritus visual analog scale (VAS), and Investigator's Global Assessment (IGA) scores. Palmoplantar involvement was observed in 44.4% of patients; after 24 weeks of treatment, 83.3% of those with palmoplantar involvement experienced complete resolution. Additionally, 37.0% of patients were overweight or obese, with no statistically significant differences in treatment efficacy.</p><p><strong>Conclusion: </strong>Tralokinumab demonstrated efficacy and safety in the treatment of moderate-to-severe AD in patients aged 12-17 years. Notably, the treatment was effective in adolescent patients with palmoplantar involvement and/or obesity.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?","authors":"Eric L Simpson, Jonathan I Silverberg, Bob Geng, José-Manuel Carrascosa, Thomas Bieber, Patrick M Brunner, Delphine Staumont-Sallé, Chao Ji, Pinaki Biswas, Claire Feeney, Irene Hernández-Martín, Francisco José Rebollo Laserna, Herwig Koppensteiner","doi":"10.1007/s13555-025-01516-w","DOIUrl":"https://doi.org/10.1007/s13555-025-01516-w","url":null,"abstract":"<p><strong>Introduction: </strong>Allergic comorbidities are common in patients with atopic dermatitis (AD). Individual trials with abrocitinib or dupilumab demonstrated efficacy and safety in patients with moderate-to-severe AD and allergic comorbidities. This post hoc analysis of the phase 3 JADE COMPARE and DARE trials compared efficacy, safety, and quality of life following abrocitinib and dupilumab treatment in adults with moderate-to-severe AD, with or without comorbid asthma, allergic rhinitis, or food allergy.</p><p><strong>Methods: </strong>Data were pooled from patients who received abrocitinib (200 mg/day) or dupilumab (300 mg/every 2 weeks) for 16 weeks with concomitant topical therapy. Assessments by self-reported asthma, allergic rhinitis, or food allergy included the proportion of patients achieving Investigator's Global Assessment of clear or almost clear (IGA 0/1), ≥ 75% improvement in Eczema Area and Severity Index (EASI-75), ≥ 4-point improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4), least squares mean change from baseline in Dermatology Life Quality Index (DLQI) and SCORing Atopic Dermatitis (SCORAD), and safety.</p><p><strong>Results: </strong>Of 1195 patients (abrocitinib, n = 588; dupilumab, n = 607), 377 (32%), 225 (19%), and 211 (18%) patients self-reported comorbid asthma, food allergy, or allergic rhinitis, respectively. Week 16 IGA 0/1 responses were comparable between patients with/without comorbidity with abrocitinib (52%/54% [with/without asthma], 50%/54% [with/without allergic rhinitis], and 53%/53% [with/without food allergy]) or dupilumab (42%/42%, 37%/43%, and 47%/41%). EASI-75 and PP-NRS4 responses and DLQI and SCORAD improvements were also comparable between patients with/without comorbidity in each treatment arm. Treatment-emergent adverse events were more common in patients with comorbidities in the abrocitinib (76%/67% [with/without asthma], 80%/67% [with/without allergic rhinitis], and 78%/67% [with/without food allergy]) and dupilumab (71%/53%, 71%/57%, and 62%/59%) arms.</p><p><strong>Conclusion: </strong>Abrocitinib and dupilumab improved AD signs and symptoms with a manageable safety profile in patients with moderate-to-severe AD, regardless of asthma, allergic rhinitis, or food allergy. Graphical Abstract available for this article.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier, NCT03720470 (JADE COMPARE) and NCT04345367 (DARE).</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}